Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients
Cells · 2024
DOI: 10.3390/cells13090782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Argyro Roumeliotou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry/Metastatic Signaling, Department of Biology, University of Patras, 26504 Patras, Greece. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplastic Cells, Circulating, Prostatic Neoplasms, Receptors, CXCR4. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund of the European Union and Greek funds through the Op-erational Program Competitiveness Entrepreneurship and Innovation, unde…, EU NextGenEU through the General Secretariat for Research and Innovation of the Hellenic Ministry of Development as part of the Hellenic Precision Medicine Net…, European Regional Development Fund of the European Union and Greek funds.
Themen: Onkologische Pflege
Abstract (Originalsprache)
CXCR4, JUNB and PD-L1 are implicated in cancer progression and metastasis. The current study investigated these biomarkers in CTCs isolated from metastatic prostate cancer (mPCa) patients at the RNA and protein levels. CTCs were isolated from 48 mPCa patients using the Ficoll density gradient and ISET system (17 out of 48). The (CK/PD-L1/CD45) and (CK/CXCR4/JUNB) phenotypes were identified using two triple immunofluorescence stainings followed by VyCAP platform analysis. Molecular analysis was conducted with an EpCAM-dependent method for 25/48 patients. CK-8, CK-18, CK-19, JUNB, CXCR4, PD-L1, and B2M (reference gene) were analyzed with RT-qPCR. The (CK+/PD-L1+/CD45-) and the (CK+/CXCR4+/JUNB+) were the most frequent phenotypes (61.1% and 62.5%, respectively). Furthermore, the (CK+/CXCR4+/JUNB-) phenotype was correlated with poorer progression-free survival [(PFS), HR: 2.5, p = 0.049], while the (CK+/PD-L1+/CD45-) phenotype was linked to decreased overall survival [(OS), HR: 262.7, p = 0.007]. Molecular analysis revealed that 76.0% of the samples were positive for CK-8,18, and 19, while 28.0% were positive for JUNB, 44.0% for CXCR4, and 48.0% for PD-L1. Conclusively, CXCR4, JUNB, and PD-L1 were highly expressed in CTCs from mPCa patients. The CXCR4 protein expression was associated with poorer PFS, while PD-L1 was correlated with decreased OS, providing new biomarkers with potential clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biochemistry/Metastatic Signaling, Department of Biology, University of Patras, 26504 Patras, Greece.
- Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
- Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
- Hellenic Oncology Research Group, 11526 Athens, Greece.
- Oncology Unit, ST Andrews General Hospital of Patras, 26332 Patras, Greece.
- Department of Oncology, Venizeleion General Hospital of Heraklion, 71409 Heraklion, Greece.
ORCID-Profile: Areti Strati, Anastasia Xagara, Stavroula Smilkou, Athanasios Kotsakis, Evi Lianidou, Galatea Kallergi
Förderung
- European Regional Development Fund of the European Union and Greek funds through the Op-erational Program Competitiveness Entrepreneurship and Innovation, unde…
- EU NextGenEU through the General Secretariat for Research and Innovation of the Hellenic Ministry of Development as part of the Hellenic Precision Medicine Net…
- European Regional Development Fund of the European Union and Greek funds
- EU NextGenEU through the General Secretariat for Research and Innovation of the Hellenic Ministry of Development
Zitieren
APA
Roumeliotou, A., Strati, A., Chamchougia, F., Xagara, A., Tserpeli, V., Smilkou, S., Lagopodi, E., Christopoulou, A., Kontopodis, E., Drositis, I., Androulakis, N., Georgoulias, V., Koinis, F., Kotsakis, A., Lianidou, E., & Kallergi, G. (2024). Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients. Cells. https://doi.org/10.3390/cells13090782
Vancouver
Roumeliotou A, Strati A, Chamchougia F, Xagara A, Tserpeli V, Smilkou S, et al. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients. Cells. 2024. doi:10.3390/cells13090782
BibTeX
@article{Roumeliotou2024,
author = {Roumeliotou, Argyro and Strati, Areti and Chamchougia, Foteini and Xagara, Anastasia and Tserpeli, Victoria and Smilkou, Stavroula and Lagopodi, Elina and Christopoulou, Athina and Kontopodis, Emmanouil and Drositis, Ioannis and Androulakis, Nikolaos and Georgoulias, Vassilis and Koinis, Filippos and Kotsakis, Athanasios and Lianidou, Evi and Kallergi, Galatea},
title = {Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13090782}
}
EUVIMED